PATENT CLAIM ANALYSIS

Application Number: 15918955
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-07
Patent Classification: ["514", "229500"]

Abstract:
The disclosure provides the use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals for the treatment of residual symptoms of psychosis or schizophrenia. The disclosure also provides novel long acting injectable formulations of particular substituted heterocycle fused gamma-carboline compounds and use of such long acting injectable formulations for the treatment of residual symptoms of psychosis or schizophrenia.

Claim (Index 51):
The long-acting injectable composition of  claim 50 , wherein the patient has not responded to treatment with one or more antipsychotic agents selected from chlorpromazine, haloperidol, droperidol, fluphenazine, loxapine, mesoridazine molindone, perphenazine, pimozide, prochlorperazine promazine, thioridazine, thiothixene, trifluoperazine, clozapine, aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone, paliperidone, asenapine, lurasidone, iloperidone, cariprazine, amisulpride, zotepine, and sertindole.

Metadata:
- Claim Count in Document: 11.0
- Percentile: 90.0
- Lexical Diversity: 2.0
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15101874', '15301895', '15467867', '12994560', '14066987']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7654604144843102
- 35 USC 102 Novelty (BERT): 0.5351018043722402
- Combined Prediction Score: 0.7424245534731032
- Mean Citation Score: 244.05284
- Max Citation Score: 368.6936
- Similarity Product: 281.97605663900373

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 0

Dataset: test